| Cases | Checkpoint inhibitor | GBS variant | Treatment | Outcome |
| Wilgenhof and Neyns [14] | Ipilimumab/CTLA-4 | AIDP | Corticosteroids | Recovery | Bot et al. [15] | Ipilimumab/CTLA-4 | AIDP | IVIG | Death | Gaudy-Marqueste et al. [16] | Ipilimumab/CTLA-4 | Enteric neuropathy | Corticosteroids, anti-TNF therapy, tacrolimus, plasmapheresis, orogastric drainage, and ventilatory assistance | Death | Jacob et al. [23] | Nivolumab/PD-1 | AIDP | IVIG, plasmapheresis, and intubation | Death | Patel et al. [17] | Ipilimumab/CTLA-4 | AIDP | Corticosteroids, IVIG | Recovery | Supakornnumporn and Katirji [18] | Combination ipilimumab+nivolumab | AIDP | Corticosteroids, IVIG, and nasogastric tube | Recovery | Wu et al. [5] | Ipilimumab/CTLA-4 | Pandysautonomia | Corticosteroids, IVIG, pressors, intubation, indwelling urinary catheter, and TPN | Recovery | Fukumoto et al. [24] | Nivolumab/PD-1 | AIDP | Corticosteroids, IVIG | Recovery | Garcia et al. [3] | Ipilimumab/CTLA-4 | AIDP | Corticosteroids | Recovery | Kyriazoglou et al. [27] | Nivolumab/PD-1 | AIDP | Corticosteroids, IVIG | Recovery | Manam et al.—2 cases [19] | Pembrolizumab/PD-1 ×2 | (1) AIDP (2) AIDP | (1) Corticosteroids, IVIG, and plasmapheresis (2) Corticosteroids, IVIG, intubation, and plasmapheresis | (1) Recovery (2) Death | Nukui et al. [25] | Nivolumab/PD-1 | AIDP | Corticosteroids, IVIG | Recovery | Ong et al. [20] | Pembrolizumab/PD-1 | AIDP | Corticosteroids, IVIG | Recovery | Thapa et al. [26] | Nivolumab/PD-1 | AIDP | Corticosteroids, IVIG, and intubation | Prevention of disease progression |
|
|